Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Clin Infect Dis ; 55(1): 33-41, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22431799

RESUMEN

BACKGROUND: Escherichia coli O157:H7 is the leading cause of hemolytic uremic syndrome (HUS). Risk factors for development of this complication warrant identification. METHODS: We enrolled children infected with E. coli O157:H7 within 1 week of the onset of diarrhea in this prospective cohort study. The study was conducted in 5 states over 9.5 years . The primary and secondary outcomes were HUS (hematocrit <30% with smear evidence of hemolysis, platelet count <150 × 10(3)/µL, and serum creatinine concentration > upper limit of normal for age) and oligoanuric HUS. Univariate and multivariable and ordinal multinomial regression analyses were used to test associations between factors apparent during the first week of illness and outcomes. RESULTS: Of the 259 children analyzed, 36 (14%) developed HUS. Univariate analysis demonstrated that children who received antibiotics during the diarrhea phase more frequently developed HUS than those who did not (36% vs 12%; P = .001). The higher rate of HUS was observed across all antibiotic classes used. In multivariable analysis, a higher leukocyte count (adjusted odds ratios [aOR] 1.10; 95% CI, 1.03-1.19), vomiting (aOR 3.05; 95% CI, 1.23-7.56), and exposure to antibiotics (aOR 3.62; 95% CI, 1.23-10.6) during the first week of onset of illness were each independently associated with development of HUS. Multinomial ordinal logistic regression confirmed that initial leukocyte count and antibiotic use were independently associated with HUS and, additionally, these variables were each associated with the development of oligoanuric HUS. CONCLUSIONS: Antibiotic use during E. coli O157:H7 infections is associated with a higher rate of subsequent HUS and should be avoided.


Asunto(s)
Infecciones por Escherichia coli/complicaciones , Escherichia coli O157/aislamiento & purificación , Síndrome Hemolítico-Urémico/microbiología , Antibacterianos/uso terapéutico , Niño , Preescolar , Infecciones por Escherichia coli/tratamiento farmacológico , Infecciones por Escherichia coli/epidemiología , Femenino , Síndrome Hemolítico-Urémico/epidemiología , Humanos , Lactante , Recién Nacido , Recuento de Leucocitos , Modelos Logísticos , Masculino , Análisis Multivariante , Oliguria/epidemiología , Estudios Retrospectivos , Factores de Riesgo , Vómitos/microbiología
2.
Pediatr Nephrol ; 24(4): 761-7, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19082635

RESUMEN

C1q nephropathy (C1qN) is an uncommon disorder seen in children and adults with nephrotic syndrome and non-specific urinary findings. It has been described with minimal change nephrotic syndrome (MCNS), focal segmental glomerulonephritis and isolated mesangial proliferative glomerulonephritis. We describe nine children with MCNS and mesangial C1q deposition. These children had a median age of 2.7 years at diagnosis (range 1.3-15 years), 56% were male and 78% were Hispanic. We compared these children to concurrent patients with nephrotic syndrome and biopsy-proven MCNS. We found that the C1qN patients were more likely than MCNS children to require chronic immunosuppression with calcineurin inhibitors or mycophenolate mofetil to maintain remission. However, all children were able to achieve and sustain clinical remission of nephrotic syndrome. Children with C1qN and minimal change histology have an increased frequency of frequently relapsing and steroid-unresponsive disease, but they can attain prolonged remission and stable renal function with calcineurin inhibitor or mycophenolate mofetil therapy.


Asunto(s)
Complemento C1q/metabolismo , Glomerulonefritis Membranoproliferativa/metabolismo , Glomeruloesclerosis Focal y Segmentaria/metabolismo , Nefrosis Lipoidea/metabolismo , Adolescente , Inhibidores de la Calcineurina , Niño , Preescolar , Estudios de Cohortes , Quimioterapia Combinada , Femenino , Glomerulonefritis Membranoproliferativa/tratamiento farmacológico , Glomeruloesclerosis Focal y Segmentaria/tratamiento farmacológico , Humanos , Inmunosupresores/uso terapéutico , Lactante , Masculino , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapéutico , Nefrosis Lipoidea/tratamiento farmacológico , Prednisolona/farmacología , Estudios Retrospectivos
3.
J Pediatr Oncol Nurs ; 24(1): 20-8, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17185398

RESUMEN

Needle phobia--fear of medical devices--is a significant problem in pediatric and adult chemotherapy patients. Stress-reducing medical devices is a new, effective cognitive therapy for needle phobia. Twenty-five pediatric and 25 adult chemotherapy patients were randomly exposed to conventional or stress-reducing decorated butterfly needles and syringes. Emotional stress responses were determined with the Visual Aversion Scale, Visual Analogue Fear Scale, Visual Analogue Anxiety Scale, and Visual Overall Stress Score for each needle and syringe design. Sixty-eight percent of the pediatric and 52% of the adult patients were overtly needle phobic, but children demonstrated significantly more aversion and stress (P < .001). Stress-reducing medical devices effectively and significantly reduced aversion, anxiety, fear, and overall stress, and were 76% effective in preventing overt needle phobia in children and 92% effective in adults (P < .001). One hundred percent of children and adults felt that stress-reducing medical devices should be available in chemotherapy clinics. Needle phobia and stress in pediatric and adult chemotherapy patients are significantly reduced by the use of stress-reducing medical devices.


Asunto(s)
Antineoplásicos/uso terapéutico , Equipos y Suministros , Agujas , Neoplasias/tratamiento farmacológico , Trastornos Fóbicos , Estrés Psicológico/prevención & control , Adulto , Antineoplásicos/administración & dosificación , Niño , Humanos , Evaluación de Resultado en la Atención de Salud
4.
Pediatr Nephrol ; 21(12): 1865-72, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17013606

RESUMEN

Normal values of glomerular filtration rate (GFR) in children are often expressed in a value adjusted to adult ideal body surface area. These values work well for many clinical situations, but in infants and children, especially those with atypical body mass, they may not accurately reflect renal function. Most body composition values in children are expressed in developmentally appropriate ranges. Absolute GFR (ml/min) also changes during childhood increasing rapidly in infancy and then gradually with age and body size. Previously, we developed a bedside equation for estimating GFR (ml/min) in children that accounted for changes with age and body size, and which correlated well with steady-state cold iothalamate GFR (ml/min) measurements: GFR (ml/min) = k(*)sqrt[(age(months) + 6)*wt (kg)/serum Cr (mg/dl)], where k=0.95 for females and 1.05 for males. In the present study GFR (ml/min) measured by iothalamate infusion was compared by correlation analysis with estimates calculated from the above equation in 566 children. This equation provides clinicians with a simple bedside method to estimate absolute GFR (ml/min).


Asunto(s)
Tasa de Filtración Glomerular/fisiología , Adolescente , Adulto , Niño , Preescolar , Interpretación Estadística de Datos , Femenino , Humanos , Lactante , Ácido Yotalámico , Masculino
5.
Kidney Int ; 61(2): 630-7, 2002 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11849406

RESUMEN

BACKGROUND: Although serum albumin is a marker for malnutrition and associated with a higher mortality in adult patients with end-stage renal disease (ESRD), the risk of death associated with serum albumin is unknown in pediatric patients with ESRD. We evaluated the association between serum albumin and death among pediatric patients initiating dialysis. METHODS: Data from the United States Renal Data System (USRDS) were used to identify all patients under the age of 18 who initiated dialysis between January 1, 1995 and December 31, 1998. Using the Cox proportional hazards models, the association between serum albumin obtained 45 days prior to dialysis initiation and death was estimated, controlling for demographic factors, dialysis modality, and anthropometric measures. RESULTS: Of 1723 patients included in the analysis, there were 93 deaths over 2953 patient-years of observation. The multivariate analysis demonstrated that each -1 g/dL difference in serum albumin between patients was associated with a 54% higher risk of death [adjusted relative risk (aRR), 1.54; 95% confidence interval (CI), 1.15 to 1.85; P=0.002]. This was independent of glomerular causes for their ESRD and other potential confounding variables. CONCLUSIONS: Pediatric patients initiating dialysis with hypoalbuminemia are at a higher risk for death. This finding persists after adjusting for glomerular causes for ESRD and other potential confounding variables. Low serum albumin at dialysis initiation is an important marker of mortality risk in pediatric ESRD patients.


Asunto(s)
Fallo Renal Crónico/sangre , Fallo Renal Crónico/mortalidad , Albúmina Sérica/metabolismo , Adolescente , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Fallo Renal Crónico/terapia , Masculino , Análisis Multivariante , Trastornos Nutricionales/sangre , Valor Predictivo de las Pruebas , Diálisis Renal , Factores de Riesgo
6.
J Rheumatol ; 29(7): 1536-42, 2002 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12136916

RESUMEN

OBJECTIVE: To determine the incidence and prevalence of neuropsychiatric systemic lupus erythematosus (NPSLE) and glomerulonephritis in ethnically diverse pediatric onset SLE inpatient and outpatient populations. METHODS: Seventy-five pediatric onset patients with SLE including Native American, Asian, Black, Spanish-American, and Caucasian subjects were evaluated prospectively and cross sectionally. During the 6 year study, 55 patients became inpatients. Subjects underwent medical interview, physical examination, laboratory review, neuropsychiatric inventory, and chart review. Classification of NPSLE was accomplished with the 1999 ACR NPSLE case definitions. RESULTS: Prospectively, NPSLE occurred in 95% of pediatric SLE patients and was more common than glomerulonephritis (55%; p < or = 0.0001). NPSLE prevalence (%) and incidence (event/person/yr) were as follows: headache 72%, 95; mood disorder 57%, 0.41; cognitive disorder 55%, 0.49; seizure disorder 51%, 0.94; acute confusional state 35%, 0.6; anxiety disorder 21%, 0.28; peripheral nervous system disorder 15%, 0.16; cerebrovascular disease 12%, 0.32; psychosis 12%, 0.16; chorea 7%, 0.01; demyelinating syndrome 4%, 0.01; and myelopathy 1%, 0.001. Cross sectionally, active NPSLE was present in 93% of inpatients and 69% of outpatients. When only serious forms of NPSLE were considered (stroke, seizures, major cognitive disorder, chorea, psychosis, major depression, acute confusional state), serious or life-threatening NPSLE occurred in 76% of all SLE subjects prospectively, and in 85% and 40% of inpatients and outpatients cross sectionally, which in each instance was more common than glomerulonephritis (p < or = 0.001). CONCLUSION: NPSLE is one of the most common serious complications of pediatric SLE, and is particularly increased in pediatric inpatients.


Asunto(s)
Lupus Eritematoso Sistémico/complicaciones , Vasculitis por Lupus del Sistema Nervioso Central/epidemiología , Vasculitis por Lupus del Sistema Nervioso Central/etiología , Adolescente , Adulto , Distribución por Edad , Edad de Inicio , Niño , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Lupus Eritematoso Sistémico/diagnóstico , Vasculitis por Lupus del Sistema Nervioso Central/diagnóstico , Masculino , Prevalencia , Probabilidad , Estudios Prospectivos , Factores de Riesgo , Índice de Severidad de la Enfermedad , Distribución por Sexo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA